Fibroblast growth factor in extremities

Michiko Tanaka, Yoshikazu Yonemitsu

研究成果: 著書/レポートタイプへの貢献

抄録

Fibroblast growth factor (FGF) is recognized as one of the major angiogenic factors. Among the FGF family members, FGF-1 (acidic fibroblast growth factor, aFGF) and FGF-2 (basic fibroblast growth factor, bFGF) have been extensively studied at both preclinical and clinical stages for applications in therapeutic angiogenesis. In vivo studies have reported various synergistic effects of FGF-2, and gene therapy has achieved promising results in early preclinical studies. However, few clinical trials have been conducted. In this chapter, we provide an overview and future perspectives of the progression of research into angiogenic gene therapy with FGF for peripheral artery disease. The focus of a new gene transfer vector based on a non-transmissible recombinant Sendai virus that expresses the human FGF-2 gene is also introduced as a frontier of therapeutic angiogenesis in this field.

元の言語英語
ホスト出版物のタイトルTherapeutic Angiogenesis
出版者Springer Singapore
ページ145-158
ページ数14
ISBN(電子版)9789811027444
ISBN(印刷物)9789811027437
DOI
出版物ステータス出版済み - 7 11 2017

Fingerprint

Fibroblasts
Gene therapy
Gene transfer
Intercellular Signaling Peptides and Proteins
Viruses
Genes

All Science Journal Classification (ASJC) codes

  • Engineering(all)
  • Computer Science(all)

これを引用

Tanaka, M., & Yonemitsu, Y. (2017). Fibroblast growth factor in extremities. : Therapeutic Angiogenesis (pp. 145-158). Springer Singapore. https://doi.org/10.1007/978-981-10-2744-4_10

Fibroblast growth factor in extremities. / Tanaka, Michiko; Yonemitsu, Yoshikazu.

Therapeutic Angiogenesis. Springer Singapore, 2017. p. 145-158.

研究成果: 著書/レポートタイプへの貢献

Tanaka, M & Yonemitsu, Y 2017, Fibroblast growth factor in extremities. : Therapeutic Angiogenesis. Springer Singapore, pp. 145-158. https://doi.org/10.1007/978-981-10-2744-4_10
Tanaka M, Yonemitsu Y. Fibroblast growth factor in extremities. : Therapeutic Angiogenesis. Springer Singapore. 2017. p. 145-158 https://doi.org/10.1007/978-981-10-2744-4_10
Tanaka, Michiko ; Yonemitsu, Yoshikazu. / Fibroblast growth factor in extremities. Therapeutic Angiogenesis. Springer Singapore, 2017. pp. 145-158
@inbook{4f9c2b46d35345a4bdd5c3bea2842f6a,
title = "Fibroblast growth factor in extremities",
abstract = "Fibroblast growth factor (FGF) is recognized as one of the major angiogenic factors. Among the FGF family members, FGF-1 (acidic fibroblast growth factor, aFGF) and FGF-2 (basic fibroblast growth factor, bFGF) have been extensively studied at both preclinical and clinical stages for applications in therapeutic angiogenesis. In vivo studies have reported various synergistic effects of FGF-2, and gene therapy has achieved promising results in early preclinical studies. However, few clinical trials have been conducted. In this chapter, we provide an overview and future perspectives of the progression of research into angiogenic gene therapy with FGF for peripheral artery disease. The focus of a new gene transfer vector based on a non-transmissible recombinant Sendai virus that expresses the human FGF-2 gene is also introduced as a frontier of therapeutic angiogenesis in this field.",
author = "Michiko Tanaka and Yoshikazu Yonemitsu",
year = "2017",
month = "7",
day = "11",
doi = "10.1007/978-981-10-2744-4_10",
language = "English",
isbn = "9789811027437",
pages = "145--158",
booktitle = "Therapeutic Angiogenesis",
publisher = "Springer Singapore",

}

TY - CHAP

T1 - Fibroblast growth factor in extremities

AU - Tanaka, Michiko

AU - Yonemitsu, Yoshikazu

PY - 2017/7/11

Y1 - 2017/7/11

N2 - Fibroblast growth factor (FGF) is recognized as one of the major angiogenic factors. Among the FGF family members, FGF-1 (acidic fibroblast growth factor, aFGF) and FGF-2 (basic fibroblast growth factor, bFGF) have been extensively studied at both preclinical and clinical stages for applications in therapeutic angiogenesis. In vivo studies have reported various synergistic effects of FGF-2, and gene therapy has achieved promising results in early preclinical studies. However, few clinical trials have been conducted. In this chapter, we provide an overview and future perspectives of the progression of research into angiogenic gene therapy with FGF for peripheral artery disease. The focus of a new gene transfer vector based on a non-transmissible recombinant Sendai virus that expresses the human FGF-2 gene is also introduced as a frontier of therapeutic angiogenesis in this field.

AB - Fibroblast growth factor (FGF) is recognized as one of the major angiogenic factors. Among the FGF family members, FGF-1 (acidic fibroblast growth factor, aFGF) and FGF-2 (basic fibroblast growth factor, bFGF) have been extensively studied at both preclinical and clinical stages for applications in therapeutic angiogenesis. In vivo studies have reported various synergistic effects of FGF-2, and gene therapy has achieved promising results in early preclinical studies. However, few clinical trials have been conducted. In this chapter, we provide an overview and future perspectives of the progression of research into angiogenic gene therapy with FGF for peripheral artery disease. The focus of a new gene transfer vector based on a non-transmissible recombinant Sendai virus that expresses the human FGF-2 gene is also introduced as a frontier of therapeutic angiogenesis in this field.

UR - http://www.scopus.com/inward/record.url?scp=85055069546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055069546&partnerID=8YFLogxK

U2 - 10.1007/978-981-10-2744-4_10

DO - 10.1007/978-981-10-2744-4_10

M3 - Chapter

AN - SCOPUS:85055069546

SN - 9789811027437

SP - 145

EP - 158

BT - Therapeutic Angiogenesis

PB - Springer Singapore

ER -